Stifel Financial Corp Has $1.91 Million Stock Holdings in Vericel Co. (NASDAQ:VCEL)

Stifel Financial Corp increased its holdings in shares of Vericel Co. (NASDAQ:VCEL - Free Report) by 23.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 34,705 shares of the biotechnology company's stock after purchasing an additional 6,632 shares during the quarter. Stifel Financial Corp owned 0.07% of Vericel worth $1,906,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of VCEL. Wellington Management Group LLP raised its stake in shares of Vericel by 119.3% during the fourth quarter. Wellington Management Group LLP now owns 1,288,921 shares of the biotechnology company's stock valued at $70,775,000 after purchasing an additional 701,064 shares during the period. Champlain Investment Partners LLC purchased a new stake in Vericel during the 4th quarter worth $34,233,000. Raymond James Financial Inc. purchased a new stake in Vericel during the 4th quarter worth $28,126,000. William Blair Investment Management LLC lifted its holdings in Vericel by 66.3% in the 4th quarter. William Blair Investment Management LLC now owns 1,258,416 shares of the biotechnology company's stock worth $69,100,000 after buying an additional 501,736 shares in the last quarter. Finally, Federated Hermes Inc. boosted its position in Vericel by 25.4% in the 4th quarter. Federated Hermes Inc. now owns 1,122,373 shares of the biotechnology company's stock valued at $61,630,000 after buying an additional 227,675 shares during the last quarter.

Vericel Price Performance

Vericel stock traded down $0.14 during midday trading on Friday, reaching $41.73. The stock had a trading volume of 974,009 shares, compared to its average volume of 403,190. The firm's fifty day simple moving average is $43.38 and its two-hundred day simple moving average is $51.15. Vericel Co. has a twelve month low of $37.39 and a twelve month high of $63.00. The firm has a market cap of $2.09 billion, a price-to-earnings ratio of 695.62 and a beta of 1.31.

Vericel (NASDAQ:VCEL - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.14). Vericel had a net margin of 1.56% and a return on equity of 1.48%. The business had revenue of $52.60 million for the quarter, compared to analyst estimates of $53.86 million. During the same period in the previous year, the firm posted ($0.08) earnings per share. The firm's quarterly revenue was up 2.6% on a year-over-year basis. As a group, sell-side analysts predict that Vericel Co. will post 0.14 EPS for the current fiscal year.

Insider Buying and Selling at Vericel

In other news, CEO Dominick Colangelo sold 24,850 shares of the company's stock in a transaction on Thursday, April 10th. The shares were sold at an average price of $41.89, for a total value of $1,040,966.50. Following the transaction, the chief executive officer now directly owns 260,354 shares of the company's stock, valued at approximately $10,906,229.06. This represents a 8.71 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 5.20% of the company's stock.

Analyst Upgrades and Downgrades

VCEL has been the topic of several recent analyst reports. Canaccord Genuity Group boosted their price target on Vericel from $64.00 to $67.00 and gave the stock a "buy" rating in a research note on Monday, February 3rd. StockNews.com upgraded shares of Vericel from a "sell" rating to a "hold" rating in a research note on Saturday, March 8th. HC Wainwright restated a "buy" rating and issued a $60.00 target price on shares of Vericel in a research note on Friday, February 28th. Truist Financial decreased their target price on Vericel from $61.00 to $51.00 and set a "buy" rating for the company in a research report on Friday, April 11th. Finally, Stephens reissued an "overweight" rating and set a $65.00 target price on shares of Vericel in a report on Wednesday, January 15th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $60.86.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.